Actuate Therapeutics

ACTU · NASDAQ

$0.6161+$0.0171 (+2.85%)TodayMarket closed · Oct 20, 7:53 PM ET

Prev close $0.599

Latest news

NewsOct 16, 1:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsOct 16, 4:46 AM ETAvi Kapoor
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
NewsOct 7, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsOct 7, 4:38 AM ETAvi Kapoor
Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
NewsOct 6, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsSep 28, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseSep 9, 7:00 AM ETGlobe Newswire
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
NewsAug 20, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
Press releaseJun 9, 7:45 AM ETGlobe Newswire
Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
Press releaseJun 1, 7:00 AM ETGlobe Newswire
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
Press releaseMay 11, 7:00 AM ETGlobe Newswire
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Press releaseMay 6, 8:45 AM ETGlobe Newswire
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
NewsApr 21, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsApr 16, 3:34 AM ETMohd Haider
Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?
NewsApr 15, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseApr 14, 8:45 AM ETGlobe Newswire
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Press releaseMar 24, 7:00 AM ETACCESS Newswire
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers
Press releaseMar 9, 8:45 AM ETGlobe Newswire
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Press releaseMar 4, 5:00 PM ETGlobe Newswire
Actuate Therapeutics to Present at The Citizens Life Sciences Conference
Press releaseFeb 24, 8:45 AM ETGlobe Newswire
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
NewsJun 27, 8:07 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsJun 26, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMar 27, 4:01 PM ETBusiness Wire
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Friday's Intraday Session

Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

12 Health Care Stocks Moving In Thursday's Intraday Session

Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

12 Health Care Stocks Moving In Tuesday's After-Market Session

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?

12 Health Care Stocks Moving In Wednesday's After-Market Session

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

Actuate Therapeutics to Present at The Citizens Life Sciences Conference

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results